Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Dermatology

The AI medical device powering a new era of skin cancer care across the NHS

THE ARTICLES ON THESE PAGES ARE PRODUCED BY BUSINESS REPORTER, WHICH TAKES SOLE RESPONSIBILITY FOR THE CONTENTS

The Independent UK

Do COVID-19 vaccines help keep you from going bald?

The COVID-19 vaccines can help keep you from getting the nasty virus, missing many days of work or school, and ending up in the hospital or the graveyard.

Tribune News Service

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

NOVN: EPI Revenue Trends Are Strong

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

Mayo Clinic Minute: Learning the ABCDEs of melanoma

Melanoma is a type of skin cancer that develops in cells that produce your skin's pigment. Regular skin checks can help you identify the warning signs and differentiate melanoma from noncancerous skin formations, according to the American Academy of Dermatology.

Tribune News Service

Is collagen worth taking? Scientists reveal the ideal method for building the protein

Our body naturally produces collagen — it's also a 2 billion dollar supplement industry. Inverse spoke to experts from the fields of orthopedics, nutrition, sports, and dermatology to separate collagen fact from fiction.

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

inkl

Read news from The Economist, FT, and more,
with one subscription

NOVN: First EPI Sales

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

People

Jay Bhattacharya

John Vandermosten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

US Food and Drug Administration

Rhythm Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play